Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-06-21
    E.g., 2018-06-21

Articles

14260 items
12:45 PM, Jun 07, 2018  |  BC Innovations | Emerging Company Profile

Radio fusion

Fusion Pharmaceuticals Inc. is improving the safety of radiopharmaceuticals for cancer by using a proprietary linker to label antibodies with the radioisotope actinium-225. While the newco remains tight-lipped about the linker’s design, SVP of Business Development...
1:35 PM, Jun 06, 2018  |  BC Innovations | Translation in Brief

Distinguishing DLBCL

A genomics-based method of subtyping diffuse large B cell lymphoma could improve prognostic predictions and identification of subtype-appropriate treatment regimens. Diffuse large B cell lymphoma (DLBCL) is clinically and genetically heterogeneous and roughly 40% of patients...
12:06 PM, Jun 06, 2018  |  BC Innovations | Distillery Therapeutics

Cardiovascular

INDICATION: Thrombosis Mouse studies suggest JAK inhibitors could help treat thrombosis in patients with JAK-2 mutations. In a mouse model of deep vein stenosis-induced thrombosis harboring a gain-of-function JAK-2 mutation, the JAK-1/JAK-2 inhibitor Jakafi ruxolitinib decreased...
12:06 PM, Jun 06, 2018  |  BC Innovations | Distillery Therapeutics

Cancer

INDICATION: Breast cancer; non-small cell lung cancer (NSCLC) Cell culture and mouse studies suggest inhibiting PHIP could help treat triple-negative breast cancer (TNBC) and NSCLC. In two human TNBC cell lines, shRNA targeting PHIP decreased colony...
12:05 PM, Jun 06, 2018  |  BC Innovations | Distillery Therapeutics

Cardiovascular

INDICATION: Myocardial infarction (MI) Cell culture and rat studies suggest pericardial fluid-treated cardiospheres could help treat MI. In primary rat cardiospheres, levels of cardiac stem cell markers and growth factors were higher when cultured in pericardial...
12:05 PM, Jun 06, 2018  |  BC Innovations | Distillery Therapeutics

Neurology

INDICATION: Amyotrophic lateral sclerosis (ALS) Cell culture studies suggest activating NFE2L2 could help treat ALS by promoting normal folding of mutant SOD1. Crystallographic analyses of an ALS-associated SOD1 mutant complexed with a library of cysteine-reactive...
12:05 PM, Jun 06, 2018  |  BC Innovations | Distillery Therapeutics

Infectious disease

INDICATION: Trypanosome Mouse studies identified a macrocyclic Trypanosoma rhodesain inhibitor that could help treat African trypanosomiasis. Screening of a library of cysteine protease inhibitors, in vitro activity and parasite culture assays, and structure-based optimization of...
12:04 PM, Jun 06, 2018  |  BC Innovations | Distillery Techniques

Imaging

TECHNOLOGY: PET An OX40-targeting PET imaging agent could help predict responses to immunotherapy in cancer. The agent consisted of a 64Cu radionuclide-labeled mouse mAb targeting OX40, a marker of T cell activation. In vitro, the agent...
12:04 PM, Jun 06, 2018  |  BC Innovations | Distillery Techniques

Biomarkers

TECHNOLOGY: Gene profiling A mutation in CAMK2A could help predict the risk of a previously undescribed neurodevelopmental disorder characterized by growth delay, frequent seizures and severe cognitive dysfunction. Genomic profiling of two children with the disease...
9:32 AM, Jun 06, 2018  |  BC Innovations | Translation in Brief

JAKs and clots

Brigham and Women’s Hospital researchers have uncovered the mechanisms behind a major complication in bone marrow disorders by linking a JAK-2 mutation with thrombosis in patients and mice, and identified a way to treat blood...

Pages